

1 **Pre-COVID-19 *ex vivo* cross-reactive IFN- $\gamma$  cellular response to SARS-CoV-2 spike**  
2 **overlapping peptides is more robust among Kenyan compared to Swedish adults**

3 **Running Title:** Pre-COVID-19 cross-reactive IFN- $\gamma$  responses to SARS-CoV-2 spike:

4 Kenyan vs. Swedish adults

5 **Authors**

6 Perpetual Wanjiku<sup>1\*</sup>, Benedict Orindi<sup>1</sup>, Jedidah Mwacharo<sup>1</sup>, James Chemweno<sup>1</sup>, Henry  
7 Karanja<sup>1</sup>, Barbara Kronsteiner<sup>2,3</sup>, Oscar Kai<sup>1</sup>, Daniel Wright<sup>4</sup>, Lynette Isabella Ochola-  
8 Oyier<sup>1,5</sup>, Christopher Sundling<sup>6,7</sup>, Susanna Dunachie<sup>2,3</sup>, George M Warimwe<sup>1,5</sup>, Anna  
9 Färnert<sup>6,7</sup>, Philip Bejon<sup>1,8</sup>, Francis M. Ndungu<sup>1,5,6†</sup>, Eunice Nduati<sup>1,5†</sup>.

10 **Affiliations**

- 11 1. Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute  
12 (KEMRI)-Wellcome Trust Research Programme, Kilifi, Kenya  
13 2. Centre for Global Health Research, Nuffield Department of Medicine, University of  
14 Oxford, Oxford, United Kingdom  
15 3. Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Thailand  
16 4. Department of Pediatrics, University of Oxford, Oxford, United Kingdom  
17 5. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine,  
18 University of Oxford, Oxford, United Kingdom  
19 6. Division of Infectious Diseases, Department of Medicine Solna, and Center for  
20 Molecular Medicine, Karolinska Institutet, Stockholm, Sweden  
21 7. Department of Infectious Diseases, Karolinska University Hospital, Stockholm,  
22 Sweden  
23 8. Modernising Medical Microbiology, Nuffield Department of Medicine, University of  
24 Oxford, Oxford, United Kingdom

25 \* Correspondence to: [pwanjiku@kemri-wellcome.org](mailto:pwanjiku@kemri-wellcome.org)

26 †These authors contributed equally.

27 **Highlights**

- 28 • Higher frequencies of cross-reactive IFN- $\gamma$ -secreting cells among Kenyan pre-  
29 COVID-19 adults compared to Sweden.  
30 • Trends of higher TNF- $\alpha$  and IFN- $\gamma$  T-cell responses among Kenyan adults.  
31 • Presence of pre-existing T-cell immunity in Sub-Saharan Africa.

32 **Abstract**

33 **Introduction**

34 Global WHO data indicate that Sub-Saharan African (SSA) countries, such as Kenya,  
35 experienced reduced coronavirus disease 2019 (COVID-19) severe-morbidity and mortality  
36 burdens relative to their more affluent counterparts in Europe, Asia, and North America.

37 **Methods**

38 We analysed peripheral blood mononuclear cells (PBMC) samples collected from Kenya and  
39 Sweden before and during COVID-19. Pre-COVID-19 samples were available for 80 adults  
40 and 10 infants from Kenya, and 20 adults from Sweden. COVID-19 samples were available  
41 for 39 Kenyan adults. The samples were analysed for *ex vivo* IFN- $\gamma$  secretion using an  
42 Enzyme-Linked Immunosorbent (ELISpot) assay following *in vitro* stimulations with  
43 overlapping SARS-CoV-2 spike-protein peptides. T-cells expressing IFN- $\gamma$ , IL-2, TNF- $\alpha$ ,  
44 CD154, and CD107a were assessed following similar stimulations, using intracellular  
45 cytokine staining (ICS) and multiparameter flow cytometry.

46 **Results**

47 55.7% of the Kenyan pre-COVID-19 adults were classified as responders by ELISPOT  
48 responses to spike-protein peptides, compared with 28% of Swedish pre-COVID-19 adults ( $p$   
49 = 0.04). The frequencies for SARS-CoV-2 spike-specific TNF- $\alpha$  CD4+, TNF- $\alpha$  CD8+ and  
50 IFN- $\gamma$  CD8+ T-cell responses, tended to be higher in the Kenyan adults although these  
51 differences did not reach statistical significance.

52 **Conclusion**

53 Pre-COVID-19 T-cell responses could contribute to lower morbidity and mortality associated  
54 with SARS-CoV-2 infections in SSA relative to Europe, Asia, and North America.

55 **Keywords:** COVID-19, SARS-CoV-2, cross-reactive responses, pre-pandemic, IFN- $\gamma$ -  
56 secreting cells, T-cells and Sub-Saharan Africa

## 57 **Introduction**

58 Most SARS-CoV-2 infections result in either asymptomatic or mild disease, but a small  
59 proportion of individuals develop severe COVID-19 requiring hospitalisation, and some of  
60 these cases result in death (1). Compared to North America, Asia and Europe, SSA  
61 experienced relatively fewer severe cases and fatalities despite many reports of similar  
62 SARS-CoV-2-infection rates (2). This paradoxical observation has puzzled many public  
63 health experts (3–5). The suggested hypotheses for the reduced burden of severe and fatal  
64 COVID-19 in SSA include potential underreporting of cases and deaths, a relatively younger  
65 population, warmer climatic conditions, and immune regulation induced from either BCG  
66 vaccinations (6–8) or previous exposures to highly inflammatory diseases like malaria (9), or  
67 cross protection from a higher level of exposure to other coronaviruses (10–16).  
68 There is evidence for cellular and humoral cross-reactivity to SARS-CoV-2 (10–16), and the  
69 role for pre-existing hCoV reactive CD4+ T-cell responses in providing SARS-CoV-2 cross  
70 protection (17). A high incidence of exposures to hCoVs and other pathogens could have  
71 induced pre-COVID-19 cross protective T-cell responses, or could have downregulated  
72 inflammation after infections of SSA residents with SARS-CoV-2 (11–16). SARS-CoV-2  
73 cross neutralising antibodies are undetectable, even in recent confirmed cases of hCoV (18).  
74 However, antigen-specific memory T-cells are more durable and frequently cross-reactive,  
75 and may play a key role in the clearance of SARS-CoV-2 infected cells (13,19,20). Recent  
76 studies, predominantly conducted in high-income countries (HICs), have reported the  
77 presence of pre-COVID-19 cross-reactive T-cell immune responses to SARS-CoV-2 with  
78 endemic hCoVs (11–15,20). Studies from SSA countries like Uganda (21,22), Senegal (23),  
79 and South Africa (24) have provided some evidence regarding pre-COVID-19 cross-reactive  
80 T-cell to SARS-CoV-2 in adults.

81 This study examined *ex vivo* pre-COVID-19 IFN- $\gamma$  cellular responses using ELISpot assay  
82 and the frequency of functional T-cells, expressing either IFN- $\gamma$ , IL-2, TNF- $\alpha$ , CD154, and  
83 CD107a by multiparametric flow cytometry following *in vitro* stimulation with overlapping  
84 SARS-CoV-2 spike peptides. Importantly, we compared results from PBMC samples  
85 collected before 2019 from Kenyan and Swedish adults, undertaking standardised assays as a  
86 single batch in the same laboratory in Kenya. We further included additional control samples  
87 from 10 Kenyan infants (<1 year) and 39 adults COVID-19 patients.

88

## 89 **Methodology**

### 90 **Study design and participants**

91 Kenyan pre-COVID-19 blood samples were collected from 80 adults and 10 infants aged  
92 below 1 year during an annual malaria surveillance cross-sectional survey conducted in  
93 March 2018 in Kilifi. The Swedish pre-COVID-19 blood samples had been collected from 20  
94 healthy adult volunteers living in Sweden between March 2012 and June 2019. At the time of  
95 pre-COVID-19 sampling, all the individuals had no symptomatic or acute infection. Post-  
96 COVID-19 positive control samples were collected from 39 Kenyan adults for studies  
97 investigating the kinetics of the immune response to SARS-CoV-2 in COVID-19 patients in  
98 Kilifi and Nairobi between 1<sup>st</sup> August 2020 and 15<sup>th</sup> February 2022. Blood was separated into  
99 plasma and PBMCs and stored at -80°C and liquid nitrogen, respectively, until used for  
100 analyses. All the participants consented for their respective samples to be used for both the  
101 contemporaneous and future research. This project received ethical approval from the Kenya  
102 Medical Research Institute's (KEMRI) Scientific and Ethics Review Unit (SERU) under  
103 protocols SERU 3149, 4081 and 4085. Ethical approval for the collection of the Swedish  
104 samples was obtained from the regional Ethics Committee in Stockholm, Sweden under  
105 protocols 2006/893-31/4 and 2019-03436.

106

107 **Overlapping SARS-CoV-2 spike peptides and in vitro stimulants for PBMC in the**

108 **ELISpot assay**

109 Pools of peptides covering the spike region 1 (S1) and spike region 2 (S2) of the SARS-CoV-  
110 2 spike protein were synthesised by Mimotopes Pty Ltd. Each peptide was 15-mers long and  
111 overlapped with the next by 10 amino acid residues. A total of 12 mini-pools, P1 to P12 (Pro-  
112 immune), which corresponded to SARS-CoV-2 spike regions S1 (P1 to P6) and S2 (P7 to  
113 P12) (25) were used. Two positive controls, phytohemagglutinin-L (PHA-L, Sigma) and anti-  
114 CD3, were used to induce a mitogenic response and demonstrate viability of lymphocytes and  
115 T-cells, respectively. A negative control (i.e., no peptide but with the Dimethyl sulfoxide  
116 [DMSO] carrier) was also included to detect non-specific IFN- $\gamma$  release. The first 10 samples  
117 with sufficient cell numbers to test against all 12 peptide pools were included in a preliminary  
118 analysis to guide peptide pool prioritisation when participant's PBMCs recovered after  
119 thawing yielded insufficient numbers for testing across all pools. Following this analysis, 4  
120 peptide pools, 3 and 4 representing S1 region, and 8 and 10 representing S2 region, were  
121 prioritised when the numbers of PBMCs were inadequate (Figure S1).

122

123 **ELISpot assay**

124 We used an IFN- $\gamma$  ELISpot assay, which quantifies the frequency of antigen-specific effector  
125 cells producing IFN- $\gamma$  after an overnight co-culture of PBMC with either specific peptides or  
126 a non-antigen specific positive control (25). Briefly, 96 well ELISpot plates (Millipore, UK)  
127 were coated with a monoclonal antibody against IFN- $\gamma$  (Mabtech, AB, Sweden) at 10 $\mu$ g/mL  
128 overnight. 200000 PBMCs per well were plated in triplicates for each individual and plates  
129 incubated at 37°C in a humidified carbon dioxide (5%) incubator for 16–18 hours of  
130 stimulation with overlapping peptide pools at 10 $\mu$ g/mL in triplicate wells. After incubation,

131 PBMCs were discarded, the plate washed, and the detector for the secreted IFN- $\gamma$  footprints  
132 on the plate membrane, anti- IFN- $\gamma$  biotinylated monoclonal antibody (Mabtech), added at  
133 1 $\mu$ g/mL and the plate incubated for 2 hours at room temperature. The plate was then washed,  
134 and streptavidin alkaline phosphatase (Mabtech) added at 1 $\mu$ g/mL, before another incubation  
135 for 1 hour at room temperature. Following washing, the 1-Step<sup>TM</sup> NBT/BCI (nitro blue  
136 tetrazolium/5-bromo-4-chloro-3-phosphatase) substrate (Thermo Scientific) was added, and  
137 the plate left in the dark for 7 minutes until the developing spots were clearly visible. The  
138 plate was then washed three times using tap water. Following overnight drying, the spots in  
139 each well were enumerated with an AID ELISpot Reader (v.4.0). Counts were presented as  
140 IFN- $\gamma$  Spot-Forming Units (SFUs) per million PBMC, which is determined by taking an  
141 average of the triplicate wells. Results are reported here as SFUs per million PBMCs after  
142 subtracting the background (mean of individual negative wells) from the antigen-specific  
143 responses. We summed up the responses from pools P3 and P4 (representing S1) and pools  
144 P8 and P10 (representing S2). For the spike region, we combined the aggregated responses  
145 from S1 and S2. Individual's assays were considered failed, and their results excluded if the  
146 negative control wells had >150 SFUs per million PBMCs, or the positive control wells had  
147 <200 SFUs per million PBMCs. An ELISpot assay limit of detection of 10 SFUs per million  
148 PBMCs was also applied, and all wells with values <10 SFUs per million PBMCs replaced  
149 with a possible minimal result equal to 5 SFUs per million PBMCs. Individuals' IFN- $\gamma$   
150 cellular responses were considered positive, if their SFUs were >71 SFUs per million PBMCs  
151 after background subtraction (corresponding to the 25<sup>th</sup> percentile of Kenyan COVID-19  
152 patients).

153 In total, 79 of 80 pre-COVID-19 Kenyan adults, 10 of 10 of the Kenyan infants, 18 of 20  
154 Swedish adults and 37 of 39 post-COVID-19 Kenyan adult patients diagnosed with COVID-  
155 19 were included in the analysis. Of participants included in the analysis, 78 (99%) pre-

156 COVID-19 Kenyan adults, 3 (30%) Kenyan infants, 5 (28%) Swedish adults and 14 (38%)  
157 COVID positive Kenyan patients had all the 12 peptide pools tested (Table S1). Due to the  
158 small number of infants, Swedish adults and COVID cases with entire 12 peptide pools  
159 tested, subsequent analyses were restricted to the prioritised pools 3 and 4 for S1 responses  
160 and pools 8 and 10 for S2 responses, and a summation of pools 3, 4, 8 and 10 for total spike  
161 responses (Figure S1).

162

### 163 **Synthetic peptide pools for intracellular cytokine staining stimulation assay**

164 A total of 178 peptides (15–18-mers with a ten amino acid overlap) spanning the entire SARS-  
165 CoV-2 spike protein (S: positions 1–178) were synthesised by Mimotopes Pty Ltd and pooled  
166 together into one pool for PBMC stimulations. DMSO was used as a negative control and  
167 PMA/ionomycin as a positive control.

168

### 169 **Intracellular cytokine staining and multi-parametric flow cytometry**

170 To determine T-cell function, we used ICS and multiparametric flow cytometry to identify  
171 and quantify effector T-cells responding to *in vitro* stimulation by overlapping SARS-CoV-2  
172 spike peptides with IL-2, IFN- $\gamma$  and TNF- $\alpha$  cytokine secretion, and upregulation of CD154  
173 and CD107a activation makers. Briefly, cryopreserved PBMCs were thawed and rested for 2–  
174 4 hours and thereafter plated at  $1 \times 10^6$  live cells per well for SARS-CoV-2 spike peptide  
175 stimulations and the DMSO, and at  $0.5 \times 10^6$  live cells per well for PMA/ionomycin in 96-  
176 well round-bottom plates. SARS-CoV-2 spike peptide stimulation was done at a final  
177 concentration of 2  $\mu\text{g/mL}$ , PMA at 0.05  $\mu\text{g/mL}$  and ionomycin (Sigma) at 0.5  $\mu\text{g/mL}$ , and  
178 DMSO (Sigma) at 2  $\mu\text{g/mL}$ . All the stimulations and controls were done in the presence of  
179 the co-stimulatory anti-CD28 and anti-CD49 (1  $\mu\text{g/mL}$ , BD Biosciences) antibodies. CD107a  
180 BV421 (0.04  $\mu\text{g/mL}$ , BD Biosciences) was added to all wells and cells incubated for 1 hour at

181 37°C temperature, 5% CO<sub>2</sub>, 95% humidity for surface staining. Following incubation,  
182 Brefeldin A (5 µg/mL, MP Biomedicals) was added, and cells incubated for a further 15  
183 hours. After washing the cells with 1X PBS, dead cells were labelled using live/dead fixable  
184 aqua dye (Invitrogen) for 30 mins at 25°C. The cells were then washed with 1X Perm/Wash  
185 before fixation and permeabilisation using Cytofix-Cytoperm for 20 mins at 4°C. Cells were  
186 washed three times with 1X Perm/Wash and then stained with APC ‘Fire’ 750 anti- CD3  
187 (Biolegend), PE Dazzle 594-anti- CD4 (Biolegend), PercpCy5.5-anti- CD8 (Biolegend),  
188 PECy7- anti-CD154 (Biolegend), APC-anti- IFN-γ (BD Biosciences), PE-anti- IL2  
189 (Biolegend) and FITC-anti- TNF-α (BD Biosciences) for 20 mins at 4°C. Cells were washed  
190 twice with 1X Perm/Wash and resuspended in 200 µl 1X PBS and stored at 4°C in the dark  
191 until acquisition. Samples were acquired on a BD LSR Fortessa (BD Biosciences) flow  
192 cytometer, and data analysed using FlowJo version 10.10.0 software. Gating strategies used  
193 are detailed in (Figure S2). Results are presented as the proportion of IFN-γ, IL-2 or TNF-α  
194 secreting CD4 or CD8 T-cells, or as the proportion of CD154 expressing CD4 T-cells or  
195 CD107a expressing CD8 T-cells after subtracting the background (values from negative  
196 control wells for each sample). A limit of detection of 0.02% was applied, and all wells with  
197 values below 0.02% were replaced with the lowest possible value of 0.01%. Boolean gates  
198 were used to examine the frequency of polyfunctional T-cells defined as CD4 or CD8 T-cells  
199 co-expressing any of the cytokines IFN-γ, TNF-α, IL-2 and surface markers CD154 or  
200 CD107a.

201

## 202 **Statistical analysis**

203 Data management and statistical analysis were performed using GraphPad Prism version  
204 10.2.3 (26). IFN-γ SFUs detected by ELISPOT were log-transformed prior to analysis. For  
205 the primary analysis, pairwise comparisons were performed between Kilifi pre-COVID-19



206 adults and Swedish pre-COVID-19 adults to assess differences in IFN- $\gamma$  SFUs, as well as the  
207 proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-  
208 CoV-2 spike peptides or its subregions (S1 or S2). A two-sample t-test was used to compare  
209 IFN- $\gamma$  SFUs as continuous variables, while Fisher's exact test was applied to compare the  
210 proportions of responders to SARS-CoV-2 spike peptides between Kilifi pre-COVID-19  
211 adults and Swedish pre-COVID-19 adults. The Mann Whitney test was used for comparisons  
212 of the proportions of cytokine-secreting T-cells and T-cell activation markers. For the  
213 secondary analysis, a one-way analysis of variance (ANOVA) with Tukey's multiple  
214 comparisons test was used to evaluate differences in IFN- $\gamma$  SFUs across all four study groups.  
215 The Kruskal Wallis test with Dunn's multiple comparisons test was used to compare the  
216 proportions of cytokine secreting T-cells and T-cell activation markers in response to SARS-  
217 CoV-2 spike peptides or subregions across the study groups. A paired t-test was used to  
218 assess interindividual variability in responses to peptides corresponding to S1 and S2. All  
219 tests were performed at 5% significance level.

## 220 **Results**

### 221 **Participants characteristics**

222 The median ages of the pre-COVID-19 study participants were 31 years (IQR 24-40 – for  
223 Kenyan adults, 33 years (IQR 31-41) for Swedish adults, and 0.75 years (IQR 0.58-0.83) for  
224 Kenyan infants. The proportions of male participants were 29% for Kenya adults, 5% for  
225 Swedish adults and 50% for Kenyan infants. Kenyan COVID-19 patients had a median age of  
226 43 years (IQR 34-55), with about one in two being male (Table S2).

227

### 228 **IFN- $\gamma$ responses by ELISpot**

229 For the S1 region, Kenyan pre-COVID-19 adults tended to have higher IFN- $\gamma$  responses (with  
230 a geometric mean of 42 [95% CI 31–56] SFUs per million PBMCs) than Swedish pre-

231 COVID adults (geometric mean of 22 [95% CI 12–39] SFUs per million PBMCs;  $p = 0.05$ ).

232 For the S2 region, Kenyan and Swedish pre-COVID-19 adults had similar geometric mean

233 responding T-cell numbers at geometric mean of 24 (95% CI: 19–30) and 27 (95% CI: 16–

234 45), SFUs per million PBMCs, respectively ( $p = 0.66$ ; Figure 1a).

235 With S1 and S2 regions combined, Kenyan pre-COVID-19 adults had higher responses

236 (geometric mean of 70 [95% CI 53–93]) than Swedish pre-COVID-19 adults (49 [95% CI

237 29–84];  $p = 0.26$ ; Figure 1b). Amongst the Kilifi pre-COVID-19 adults there were higher S1

238 responses compared to S2 responses (geometric mean of 42 [95% CI 31–56] vs. 24 [95% CI

239 19–30] SFUs per million PBMCs;  $p < 0.0001$ ) (Figure S3a). For the Swedish pre-COVID-19

240 and infants pre-COVID-19, the magnitude of S1 and S2 responses were similar (Figures S3a–

241 c).

242 We next analysed the proportion of responders within each subgroup. Responders were

243 defined as individuals with IFN- $\gamma$  SFUs responses exceeding 71 SFU per million PBMCs

244 after background subtraction, corresponding to the 25th percentile of Kenyan COVID-19

245 patients. Notably, 55.7% of the Kenyan pre-COVID-19 adults were classified as responders,

246 which was significantly higher than 28% of Swedish pre-COVID-19 adults ( $p = 0.04$ ) in

247 response to SARS-CoV-2 spike peptides. Among Kenyan pre-COVID-19 infants, 40% were

248 responders. As expected, a large proportion, 75.7% of the COVID-19 positive individuals

249 were classified as responders (Figure 1c).

250

### 251 **Cross reactive cytokine responses to SARS-CoV-2 peptides by ICS**

252 To establish whether the IFN- $\gamma$  responses observed by ELISpot were from memory T-cells

253 and whether other cytokines were secreted, we incorporated ICS assay followed by

254 multiparametric flow cytometry. Our data show that both CD4+ and CD8+ T-cells from the

255 different groups produced IFN- $\gamma$ , TNF- $\alpha$  and IL-2 after incubation with overlapping SARS-

256 CoV-2 spike peptides. CD4<sup>+</sup> T-cells also upregulated CD154 an activation marker. Kenyan  
257 pre-COVID-19 adults exhibited higher cytokines levels for IFN- $\gamma$  and TNF- $\alpha$  responses,  
258 though not statistically significant (Figure 2). For the IFN- $\gamma$  CD8<sup>+</sup> T-cell responses, Kenyan  
259 pre-COVID-19 adults had a higher median of 0.06% (IQR 0.01–0.54%) compared to  
260 Swedish pre-COVID-19 adults (median: 0.01% [IQR 0.01–0.4%];  $p = 0.54$ ). The TNF- $\alpha$   
261 CD4<sup>+</sup> T-cell responses were higher in Kenyan pre-COVID-19 adults (median: 0.03% [IQR  
262 0.01–0.095%]) than Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01–0.055%];  $p$   
263 = 0.39). Similarly, TNF- $\alpha$  CD8<sup>+</sup> T-cell responses were elevated in Kenyan pre-COVID-19  
264 adults (median: 0.06% [IQR 0.01–0.17%]) compared to Swedish pre-COVID-19 adults  
265 (median: 0.03% [IQR 0.01–0.05%];  $p = 0.13$ ) (Figure 2b, c–d). The Kenyan COVID-19  
266 patients had significantly higher TNF- $\alpha$  CD4<sup>+</sup> T-cells levels (median: 0.26% [IQR 0.11–  
267 0.73%]) compared to Kenyan pre-COVID-19 adults, (median: 0.03% [IQR 0.01–0.095%];  
268  $p=0.01$ ), Kenyan pre-COVID-19 infants (median: 0.02% [IQR 0.01–0.04%];  $p= 0.007$ ) and  
269 Swedish pre-COVID-19 adults (median: 0.015% [IQR 0.01–0.055%];  $p= 0.005$ ) (Figure 2c).  
270 IL-2 CD4<sup>+</sup> T-cell frequencies were also higher in Kenyan COVID-19 patients (median:  
271 0.09% [IQR 0.015–0.515%]) compared to Kenyan pre-COVID-19 adults (median: 0.01%  
272 [IQR 0.01–0.025%];  $p= 0.02$ ) and Swedish pre-COVID-19 adults (median: 0.01% [IQR  
273 0.01–0.01%];  $p= 0.004$ ) (Figure 2e).  
274 Our analysis of the number of functional markers co-expressed by these T-cells showed that  
275 only a small proportion of individuals showed polyfunctionality prior to COVID-19.  
276 Individuals analysed post COVID-19 had better CD4 and CD8 T-cell polyfunctionality.  
277 Compared to Swedish pre-COVID-19 adults, a higher proportion of Kenyan pre-COVID-19  
278 adults had polyfunctional CD4<sup>+</sup> and CD8<sup>+</sup> T-cells (Figure S4a, b). Collectively, these data  
279 suggest that the pre-COVID-19 CD4<sup>+</sup> and CD8<sup>+</sup>T-cells from Swedish adults were less  
280 primed to secrete TNF- $\alpha$  and IFN- $\gamma$  compared to those of the Kenyan pre-COVID-19 adults.

## 281 **Discussion**

282 We compared the frequencies and prevalence of SARS-CoV-2 cross-reactive T-cell  
283 responses by measuring IFN- $\gamma$  responses by ELISPOT and phenotypic and functional  
284 characterization by flow cytometry in pre-COVID-19 PBMC collected in Kenya, and in  
285 Sweden. We observed higher S1 specific and full spike frequencies, and a greater prevalence,  
286 of pre-pandemic SARS-CoV-2 spike peptide specific cross-reactive IFN- $\gamma$  secreting cells  
287 measured by an ELISpot assay in Kenyan adults, compared to Swedish adults. Overall, these  
288 data suggest that Kenyan pre-COVID-19 adults had higher IFN- $\gamma$  SFU responses to the S1  
289 and spike regions but similar S2 responses compared to Swedish pre-COVID-19 adults. A  
290 larger proportion of Kenyan pre-COVID-19 adults also responded to SARS-CoV-2 spike  
291 peptides. Responses to S1-specific S2-specific, and to the full spike region increased  
292 following contact with COVID-19. These findings suggest a greater pre-pandemic exposure  
293 to S1-like epitopes in Kenya contributing to SARS-CoV-2 cross-reactive T-cell responses  
294 compared to Sweden.

295 We confirmed, using ICS assay, that the spike-peptide specific IFN- $\gamma$  secreting cells included  
296 both CD4+ and CD8+ T-cells. Furthermore, we did not identify evidence that the Kenyan  
297 pre-COVID-19 adults had statistically significantly higher frequencies of pre-pandemic  
298 SARS-CoV-2 spike-specific TNF- $\alpha$ , or IFN- $\gamma$  responses either in CD4+ T-cell responses or  
299 CD8+ T-cell responses compared to their Swedish counterparts. However, the ELISPOT  
300 assay is more sensitive than the ICS assay we used, and therefore the power to detect  
301 differences between populations is more limited in the ICS work.

302 The higher frequencies and prevalence of IFN- $\gamma$  secreting cells among the Kenyan pre-  
303 pandemic adult-PBMCs compared to their Swedish counterparts is consistent with higher  
304 levels of pre-existing anti-SARS-CoV-2 cross protective immunity in SSA. These higher  
305 frequencies of pre-pandemic SARS-CoV-2 cross reactive cells may contribute to the lower

306 prevalence of severe COVID-19 and deaths in Kenya relative to European countries like  
307 Sweden. This idea is consistent with previous observations of protection from severe  
308 COVID-19 by recent exposures to endemic hCoVs (27). Furthermore, mechanistic studies in  
309 mice demonstrated that hCoV-specific, SARS-CoV-2-cross-reactive T-cells contribute to  
310 SARS-CoV-2 immune responses upon infection and vaccination (17).

311 There is little evidence for a role for cross-reactive neutralising antibodies as these are rare,  
312 even where there is PCR evidence for recent hCoV infection (18). The mechanism by which  
313 SARS-CoV-2 cross reactive CD4+ T-cells lower COVID-19 severity may include various  
314 mechanisms such as the direct killing of virus infected cells, or through their ability to offer  
315 CD8 T cells help and protecting against infection, or both, thus reducing viral loads (28–30).  
316 Alternatively (or in addition), SARS-CoV-2 cross reactive memory CD4+ T-cells may  
317 provide the necessary costimulatory molecules for helping rapid and amnestic production of  
318 protective antibodies (17).

319 This study has a few limitations. First, for the ICS assays, we only had access to PBMC from  
320 21 Kenyan pre-covid-19 adults, 10 Kenyan pre-covid-19 infants, 10 Swedish pre-covid-19  
321 adults and 9 Kenyan covid-19 adults, which reduced the statistical power of comparing  
322 responses among the groups. Second, we were only able to use spike peptides to stimulate  
323 PBMCs as the numbers of cells was limiting, it would have been more comprehensive to  
324 include other SARS-CoV-2 proteins.

325

## 326 **Conclusion**

327 We report higher frequencies and prevalence of pre-COVID-19 SARS-CoV-2 spike cross-  
328 reactive IFN- $\gamma$  secreting cells, some of which include CD8+ T-cells, among Kenyan  
329 compared to Swedish adults. This raises the possibility that higher levels of cross-protective  
330 cellular responses in SSA could explain, at least in part, why there was less severe morbidity

331 and mortality on the continent relative to Europe, Asia and North America. Nonetheless,  
332 subsequent studies including relatively higher samples sizes of pre-COVID-19 PBMC from  
333 SSA and a few more countries from Europe and/or America are required to confirm these  
334 findings and extend the research into investigating the actual mechanism of the SARS-CoV-2  
335 cross-protection. Importantly, such studies will provide new insights on how to develop novel  
336 cross-protective vaccines against similar pathogens, like coronaviruses.

337

### 338 **Acknowledgments**

339 We thank the field workers, laboratory staff and healthcare workers involved in the blood  
340 sampling. We appreciate all the study participants.

341

### 342 **Competing Interests**

343 No competing interests to declare.

344

### 345 **Funding Statement**

346 This study/project is funded by the EDCTP2 Programme (grant number RIA2020EF-3042)  
347 which is supported by the European Union, and the Swedish International Development  
348 Cooperation Agency.

349 SJD is supported by an NIHR Global Health Research Professorship (NIHR300791).

350

351

### 352 **References**

353 1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus  
354 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases

- 355 From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020 Apr  
356 7;323(13):1239–42.
- 357 2. Cabore JW, Karamagi HC, Kipruto HK, Mungatu JK, Asamani JA, Droti B, et al.  
358 COVID-19 in the 47 countries of the WHO African region: a modelling analysis of past  
359 trends and future patterns. *Lancet Glob Health*. 2022 Aug;10(8):e1099–114.
- 360 3. Osayomi T, Adeleke R, Akpoterai LE, Fatayo OC, Ayanda JT, Moyin-Jesu J, et al. A  
361 Geographical Analysis of the African COVID-19 Paradox: Putting the Poverty-as-a-  
362 Vaccine Hypothesis to the Test. *Earth Syst Environ*. 2021 Sep 1;5(3):799–810.
- 363 4. Ghosh D, Bernstein JA, Mersha TB. COVID-19 pandemic: The African paradox. *J Glob*  
364 *Health*. 10(2):020348.
- 365 5. Maeda JM, Nkengasong JN. The puzzle of the COVID-19 pandemic in Africa. *Science*.  
366 2021 Jan;371(6524):27–8.
- 367 6. Wamai RG, Hirsch JL, Van Damme W, Alnwick D, Bailey RC, Hodgins S, et al. What  
368 Could Explain the Lower COVID-19 Burden in Africa despite Considerable Circulation  
369 of the SARS-CoV-2 Virus? *Int J Environ Res Public Health*. 2021 Aug 16;18(16):8638.
- 370 7. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe  
371 coronavirus disease 2019 (COVID-19). *Proc Natl Acad Sci U S A*. 2020 Jul  
372 28;117(30):17720–6.
- 373 8. Gonzalez-Perez M, Sanchez-Tarjuelo R, Shor B, Nistal-Villan E, Ochando J. The BCG  
374 Vaccine for COVID-19: First Verdict and Future Directions. *Front Immunol*. 2021 Mar  
375 8;12:632478.
- 376 9. Tapela K, Prah DA, Tetteh B, Nuokpem F, Dosoo D, Coker A, et al. Cellular immune  
377 response to SARS-CoV-2 and clinical presentation in individuals exposed to endemic  
378 malaria. *Cell Reports*. 2024 Aug 27;43(8):114533.

- 379 10. Ashworth J, Mathie D, Scott F, Mahendran Y, Woolhouse M, Stoevesandt O, et al.  
380 Peptide microarray IgM and IgG screening of pre-SARS-CoV-2 human serum samples  
381 from Zimbabwe for reactivity with peptides from all seven human coronaviruses: a cross-  
382 sectional study. *The Lancet Microbe*. 2023 Apr 1;4(4):e215–27.
- 383 11. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-  
384 reactive T -cells in healthy donors and patients with COVID-19. *Nature*. 2020 Nov  
385 12;587(7833):270–4.
- 386 12. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-  
387 specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.  
388 *Nature*. 2020 Aug;584(7821):457–62.
- 389 13. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets  
390 of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease  
391 and Unexposed Individuals. *Cell*. 2020 Jun 25;181(7):1489-1501.e15.
- 392 14. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al.  
393 Phenotype and kinetics of SARS-CoV-2–specific T -cells in COVID-19 patients with  
394 acute respiratory distress syndrome. *Science Immunology*. 2020 Jun 26;5(48):eabd2071.
- 395 15. Mateus J, Grifoni A, Tarke A, Sidney J, Ramirez SI, Dan JM, et al. Selective and cross-  
396 reactive SARS-CoV-2 T cell epitopes in unexposed humans. *Science*. 2020 Oct  
397 2;370(6512):89–94.
- 398 16. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell*. 2021  
399 Feb;184(4):861–80.
- 400 17. Loyal L, Braun J, Henze L, Kruse B, Dingeldej M, Reimer U, et al. Cross-reactive CD4+  
401 T -cells enhance SARS-CoV-2 immune responses upon infection and vaccination.  
402 *Science*. 2021 Oct 8;374(6564):eabh1823.



- 403 18. Poston D, Weisblum Y, Wise H, Templeton K, Jenks S, Hatzioannou T, et al. Absence  
404 of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in  
405 Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. *Clin*  
406 *Infect Dis.* 2021 Sep 7;73(5):e1208–11.
- 407 19. de Candia P, Prattichizzo F, Garavelli S, Matarese G. T -cells: Warriors of SARS-CoV-2  
408 Infection. *Trends Immunol.* 2021 Jan;42(1):18–30.
- 409 20. Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al.  
410 Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild  
411 COVID-19. *Cell.* 2020 Oct 1;183(1):158-168.e14.
- 412 21. Namuniina A, Muyanja ES, Biribawa VM, Okech BA, Ssemaganda A, Price MA, et al.  
413 Proportion of Ugandans with pre-pandemic SARS-CoV-2 cross-reactive CD4+ and  
414 CD8+ T-cell responses: A pilot study. *PLOS Global Public Health.* 2023 Aug  
415 16;3(8):e0001566.
- 416 22. Nantambi H, Sembera J, Ankunda V, Ssali I, Kalyebi AW, Oluka GK, et al. Pre-  
417 pandemic SARS-CoV-2-specific IFN- $\gamma$  and antibody responses were low in Ugandan  
418 samples and significantly reduced in HIV-positive specimens. *Front Immunol [Internet].*  
419 2023 Apr 19 [cited 2024 Sep 23];14. Available from:  
420 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1148877/](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1148877/full)  
421 full
- 422 23. Herrera BB, Chaplin B, MBoup S, Abdullahi A, He M, Fisher SM, et al. West African  
423 pre-pandemic cross-reactive antibody and cellular responses against SARS-CoV-2  
424 [Internet]. *medRxiv*; 2024 [cited 2024 Sep 23]. p. 2024.05.21.24307417. Available from:  
425 <https://www.medrxiv.org/content/10.1101/2024.05.21.24307417v1>
- 426 24. Nunes MC, Johnson MJ, Kwatra G, Weinberg A, Madhi SA. T-cell responses to SARS-  
427 CoV-2 in unexposed South African women. *Gates Open Res.* 2022 Jul 13;5:150.


- 428 25. Ogbe A, Kronsteiner B, Skelly DT, Pace M, Brown A, Adland E, et al. T cell assays  
429 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral  
430 responses. *Nat Commun.* 2021 Apr 6;12(1):2055.
- 431 26. Graph pad prism programming team. Graph pad Prism, Boston, Massachusetts, USA.  
432 2023 [cited 2024 Apr 11]. Prism - GraphPad. Available from:  
433 <https://www.graphpad.com/features>
- 434 27. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic  
435 coronavirus infection is associated with less-severe COVID-19. *J Clin Invest* [Internet].  
436 2021 Jan 4 [cited 2024 Oct 30];131(1). Available from:  
437 <https://www.jci.org/articles/view/143380>
- 438 28. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol.* 2022  
439 Feb;23(2):186–93.
- 440 29. Wyllie D, Jones HE, Mulchandani R, Trickey A, Taylor-Phillips S, Brooks T, et al.  
441 SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated  
442 with protection from COVID-19: A prospective cohort study in keyworkers [Internet].  
443 medRxiv; 2021 [cited 2024 Sep 20]. p. 2020.11.02.20222778. Available from:  
444 <https://www.medrxiv.org/content/10.1101/2020.11.02.20222778v2>
- 445 30. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, et al. Cross-reactive  
446 memory T -cells associate with protection against SARS-CoV-2 infection in COVID-19  
447 contacts. *Nat Commun.* 2022 Jan 10;13(1):80.

448

## 449 **Figures**

450 **Figure 1. Comparison of the frequencies of IFN-gamma secreting cell responses to**  
451 **SARS-CoV-2 Spike regions 1 and 2 among study groups. a** frequencies of Spike regions 1  
452 and 2 separately, **b** aggregated frequencies of Spike regions 1 and 2, **c** Responders (Cut off

453 for responders is 25<sup>th</sup> percentile of Spike in CoV-adults). Comparisons done using t-test,  
454 ordinary one-way ANOVA with Tukey's multiple comparisons test and Fisher's exact test.  
455 Black line shows Geometric mean.



456

457

458 **Figure 2. Proportions of T cells expressing cytokines and surface markers in response to**

459 **SARS-CoV-2 Spike protein.** i) Cytokine responses levels of **a** IFN- $\gamma$  in CD4+ T cells, **b**


460 IFN- $\gamma$  in CD8+ T cells, **c** TNF in CD4+ T cells, **d** TNF in CD8+ T cells, **e** IL-2 in CD4+ T

461 cells, **f** IL-2 in CD8+ T cells ii) Surface markers **g** CD154 on activated CD4+ T cells **h**

462 CD107a on CD8+ T cells.

463 Number of participants for: Kilifi pre-covid adults = 21, Kilifi pre-covid infants = 11, Sweden

464 pre-covid adults = 10, Covid-19 adults = 9. Black line shows median.



465

466